More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Sigrid Carlsson, MD, PhD, MPH

Assistant Attending Epidemiologist

Sigrid Carlsson, MD, PhD, MPH Assistant Attending Epidemiologist

Office Phone

646-888-8250

Dr. Carlsson’s research is focused on screening and early detection of prostate cancer. She is an investigator in the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer. Dr. Carlsson’s research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, through the use of multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging. Her work, together with Dr. Vickers, on how the benefits and harms of prostate cancer screening varies by PSA levels at age 60 and how re-screening intervals can be adapted accordingly, was published in the British Medical Journal and has helped inform the screening guidelines in place at MSK as well as national guidelines in Sweden. Dr. Carlsson is particularly interested in implementation science and implementing established knowledge into routine clinical care, including educational efforts directed at physicians and patients.

Publications

Selected peer-reviewed publications:


  1. Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H. (2017) Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. Eur Urol. 1, 46-52.

  2. Carlsson S, Assel M, Sjoberg D, Ulmert H, Hugosson J, Lilja H, Vickers A. (2014) Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ. 348, g2296.

  3. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, & Hugosson J. (2012) Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 30, 2581-4.

  4. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ. (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 367, 595-605.

  5. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, & Lilja H. (2010) Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 11, 725-32.

For a complete list of publications:

https://www.ncbi.nlm.nih.gov/sites/myncbi/1baZsSJozosAq/bibliography/48753905/public/?sort=date&direction=ascending